Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Identification of biological markers able to better stratify cardiovascular risks in SLE patients is needed. We aimed to determine whether serum cardiac troponin T (cTnT) levels measured with a highly sensitive assay [high sensitivity cTnT (HS-cTnT)] may predict cardiovascular events (CVEs) in SLE.

Method: All SLE patients included between 2007 and 2010 in the randomized, double-blind, placebo-controlled, multicentre PLUS trial were screened. Patients with no past history of CVE at inclusion and a follow-up period of >20 months were analysed. HS-cTnT concentration was measured using the electrochemiluminescence method on serum collected at PLUS inclusion. The primary outcome was the incident CVE. Factors associated with the primary outcome were identified and multivariate analysis was performed.

Results: Overall, 442 SLE patients (of the 573 included in the PLUS study) were analysed for the primary outcome with a median follow up of 110 (interquartile range: 99-120) months. Among them, 29 (6.6%) experienced at least one CVE that occurred at a median of 67 (interquartile range: 31-91) months after inclusion. Six out of 29 patients had more than one CVE. In the multivariate analysis, dyslipidaemia, age and HS-cTnT were associated with the occurrence of CVE. Kaplan-Meier analysis showed that a concentration of HS-cTnT > 4.27 ng/l at inclusion increased by 2.7 [hazard ratio 2.7 (95% CI: 1.3, 5.6), P =0.0083] the risk of CVE in SLE.

Conclusion: HS-cTnT measured in serum is the first identified biomarker independently associated with incident CVE in SLE patients.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa434DOI Listing

Publication Analysis

Top Keywords

sle patients
16
primary outcome
12
highly sensitive
8
serum cardiac
8
cardiac troponin
8
cardiovascular events
8
incident cve
8
multivariate analysis
8
interquartile range
8
patients
7

Similar Publications

Challenges in the Diagnosis of Systemic Lupus Erythematosus.

Clin Med (Lond)

September 2025

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address:

Systemic lupus erythematosus (SLE) is a life-long, complex, multi-system, autoimmune condition which can occur at any age, most commonly in female adults in their reproductive years. Diagnosis is often delayed with reported time from symptom onset to diagnosis as long as 6 years. Delayed diagnosis can result in irreversible organ damage, acute hospital admission, poor health-related outcomes and increased risk of mortality.

View Article and Find Full Text PDF

ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease.

Ann Rheum Dis

September 2025

Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Rheumatology, Oslo University Hospital, Oslo, Norway. Electronic address:

Background: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care.

Methods: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies.

View Article and Find Full Text PDF

Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study.

Semin Arthritis Rheum

August 2025

Grupo IRIDIS (Investigation in Rheumatology and Immune-Diseases), Instituto de Investigación Sanitaria Galicia Sur, (IISGS), Hospital Universitario Vigo, Vigo, Spain.

Introduction: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where cluster analysis of autoantibodies could identify prognostic subtypes.

Objectives: To define and describe serological clusters and their clinical-epidemiological characteristics, as well as their association with comorbidities, disease activity measures, severity, and damage.

View Article and Find Full Text PDF

Objectives: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder often complicated by vascular events, with or without antiphospholipid antibody syndrome (APS). This study aimed to explore subclinical venous involvement in SLE using biochemical and imaging modalities, focusing on vein wall thickness (VWT) and inflammation-related biomarkers.

Methods: In this cross-sectional study, 68 SLE patients were categorized based on antiphospholipid antibody (APA) status and clinical APS.

View Article and Find Full Text PDF

Transverse myelitis (TM) is an inflammatory disorder of the spinal cord often associated with autoimmune diseases, such as systemic lupus erythematosus (SLE) or neuromyelitis optica spectrum disorder (NMOSD); however, it is rarely linked to rheumatoid arthritis (RA). We present the case of a 28-year-old woman with subacute ascending numbness, lancinating pain, and bilateral lower extremity weakness resulting in significant functional impairment. Despite upper motor neuron signs on examination and supportive cerebrospinal fluid findings, including elevated gamma globulins and positive myelin basic protein, spinal MRI remained negative.

View Article and Find Full Text PDF